{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:11:20Z","timestamp":1782364280359,"version":"3.54.5"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA038493, DA009789"],"award-info":[{"award-number":["DA038493, DA009789"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA017259"],"award-info":[{"award-number":["DA017259"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA032933"],"award-info":[{"award-number":["DA032933"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA033934-01A1"],"award-info":[{"award-number":["DA033934-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.neuropharm.2016.11.015","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T09:31:42Z","timestamp":1480066302000},"page":"156-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice"],"prefix":"10.1016","volume":"114","author":[{"given":"Jenny L.","family":"Wilkerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab A.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah J.","family":"Niphakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael L.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Cravatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron H.","family":"Lichtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.11.015_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid-opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bph.13337","article-title":"Actions of the dual FAAH\/MAGL inhibitor JZL195 in a murine neuropathic pain model","volume":"173","author":"Adamson Barnes","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib76","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/sj.npp.1301630","article-title":"Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala","volume":"33","author":"Alvarez-Jaimes","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neuropharm.2013.12.018","article-title":"Actions of the dual FAAH\/MAGL inhibitor JZL195 in a murine inflammatory pain model","volume":"81","author":"Anderson","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra025411","article-title":"Opioid therapy for chronic pain","volume":"349","author":"Ballantyne","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib78","series-title":"Statistics in Biology","first-page":"439","author":"Bliss","year":"1967"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FBP.0b013e3283618ac8","article-title":"Changes in morphine reward in a model of neuropathic pain","volume":"24","author":"Cahill","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib6","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1523\/JNEUROSCI.4403-06.2007","article-title":"Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration","volume":"27","author":"Caille","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.j.pain.0000460303.63948.8e","article-title":"The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain","volume":"156","author":"Campbell","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib8","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.V92.10.3605","article-title":"Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation","volume":"92","author":"Carayon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J.\u00a0Neurosci. Meth."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/jpet.102.046870","article-title":"Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol","volume":"305","author":"Cichewicz","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib11","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1073\/pnas.161191698","article-title":"Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase","volume":"98","author":"Cravatt","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-207458","article-title":"Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use-buprenorphine\/naloxone treatment and recovery in a surgical patient","author":"Conroy","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2007.04.010","article-title":"Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat","volume":"567","author":"Cox","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/bjp.2008.175","article-title":"The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors","volume":"154","author":"da Fonseca Pacheco","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugalcdep.2014.11.031","article-title":"Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study","volume":"147","author":"Degenhardt","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses Paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bjp.2008.322","article-title":"Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model","volume":"155","author":"Desroches","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib18","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/0929867306666220401141630","article-title":"Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids","volume":"6","author":"Di Marzo","year":"1999","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib20","series-title":"Neurobiology of Opioid Dependence in Creating Addiction Vulnerability","first-page":"5","author":"Evans","year":"2016"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(96)00891-5","article-title":"Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat","volume":"393","author":"Felder","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.drugalcdep.2014.11.015","article-title":"Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice","volume":"146","author":"Gamage","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib24","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.neubiorev.2013.08.006","article-title":"The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways","volume":"37","author":"Garland","year":"2013","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/jpet.115.222851","article-title":"Full fatty acid amide hydrolase inhibition combined with partial monoacylglycerol lipase inhibition: augmented and sustained antinociceptive effects with reduced cannabimimetic side effects in mice","volume":"354","author":"Ghosh","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"163","author":"Guindon","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2012.10.013","volume":"67","author":"Guindon","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib28","series-title":"Drug-poisoning Deaths Involving Heroin: United States, 2000-2013","first-page":"1","author":"Hedegaard","year":"2015"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1469-7793.2001.0731e.x","article-title":"Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons","volume":"532","author":"Huang","year":"2001","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.114.222315","article-title":"Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice","volume":"353","author":"Ignatowska-Jankowska","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J.\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpainsymman.2012.07.014","article-title":"An open-label extension study to investigate the long-term safety and tolerability of THC\/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics","volume":"46","author":"Johnson","year":"2013","journal-title":"J.\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib34","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1523\/JNEUROSCI.21-23-09506.2001","article-title":"Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission","volume":"21","author":"Katona","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1523\/JNEUROSCI.4298-03.2004","article-title":"Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons","volume":"24","author":"Khasabova","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib36","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib37","first-page":"1420","article-title":"Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms","volume":"11","author":"Kinsey","year":"2010","journal-title":"J.\u00a0Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/jpet.110.175778","article-title":"Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice","volume":"338","author":"Kinsey","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib40","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0022-3565(25)13256-4","article-title":"Pharmacology and stereoselectivity of structurally novel cannabinoids in mice","volume":"247","author":"Little","year":"1988","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.chembiol.2009.05.009","article-title":"Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism","volume":"16","author":"Long","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib42","doi-asserted-by":"crossref","first-page":"20270","DOI":"10.1073\/pnas.0909411106","article-title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in\u00a0vivo","volume":"106","author":"Long","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","article-title":"\u201cEvery 'never' I ever said came true\u201d: transitions from opioid pills to heroin injecting","volume":"25","author":"Mars","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-010-2110-6","article-title":"New operant model of reinstatement of food-seeking behavior in mice","volume":"215","author":"Martin-Garcia","year":"2011","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib46","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/j.1476-5381.2012.01948.x","article-title":"Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells","volume":"166","author":"Merighi","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1124\/jpet.112.191478","article-title":"Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice","volume":"342","author":"Miller","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/jpet.108.143487","article-title":"Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception","volume":"329","author":"Naidu","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib49","first-page":"254","article-title":"Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy","volume":"9","author":"Narang","year":"2008","journal-title":"J.\u00a0Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1021\/cn200089j","article-title":"O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors","volume":"3","author":"Niphakis","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib51","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1016\/j.bmcl.2008.08.007","article-title":"Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels","volume":"18","author":"Nomura","year":"2008","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1209200","article-title":"Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation","volume":"334","author":"Nomura","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.115.229492","article-title":"Discriminative stimulus properties of the endocannabinoid catabolic enzyme inhibitor SA-57 in mice","volume":"358","author":"Owens","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuint.2008.08.005","article-title":"CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain","volume":"53","author":"Paldy","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib55","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/npp.2012.269","article-title":"Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice","volume":"38","author":"Ramesh","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.111.181370","article-title":"Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice","volume":"339","author":"Ramesh","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjp.0706757","article-title":"Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis","volume":"148","author":"Rios","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib58","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.pain.2013.05.004","article-title":"Buprenorphine\/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone","volume":"154","author":"Roux","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/nmo.12563","article-title":"The effect of FAAH, MAGL, and Dual FAAH\/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents","volume":"27","author":"Sakin","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.phrs.2012.02.012","article-title":"Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions","volume":"65","author":"Sasso","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/taap.1996.8034","article-title":"Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system","volume":"142","author":"Schatz","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/nn.2616","article-title":"Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system","volume":"13","author":"Schlosburg","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00213-008-1184-x","article-title":"A\u00a0reliable method to study cue-, priming-, and stress-induced reinstatement of cocaine self-administration in mice","volume":"199","author":"Soria","year":"2008","journal-title":"Psychopharmacol. Berl."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.11.015_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/3-540-26573-2_11","article-title":"Effects of cannabinoids on neurotransmission","author":"Szabo","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib66","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and application","volume":"298","author":"Tallaria","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallaria","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/joim.12345","article-title":"Reflections on the role of opioids in the treatment of chronic pain: a shared solution for prescription opioid abuse and pain","volume":"278","author":"Thomas","year":"2014","journal-title":"J.\u00a0Intern Med."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1476-5381.2010.00716.x","article-title":"Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase","volume":"160","author":"Thors","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib70","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib71","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.pain.2012.02.015","article-title":"Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels","volume":"153","author":"Wilkerson","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.115.229971","article-title":"The selective monoacylglycerol lipase inhibitor MJN110 produces opioid sparing effects in a mouse neuropathic pain model","volume":"357","author":"Wilkerson","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.pbb.2012.10.002","article-title":"The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids","volume":"103","author":"Wilson-Poe","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2016.11.015_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuropharm.2007.06.003","article-title":"Evaluation of fatty acid amides in the carrageenan-induced paw edema model","volume":"54","author":"Wise","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.11.015_bib75","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","article-title":"Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice","volume":"96","author":"Zimmer","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816305123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816305123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T21:31:24Z","timestamp":1749763884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816305123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":78,"alternative-id":["S0028390816305123"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.11.015","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}